Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nano firm teams with WFU to accelerate drug discovery

Abstract:
The Business Journal of the Greater Triad Area
By Matt Evans, Staff Writer

A New Jersey firm is relocating to the Triad to commercialize technology discovered at Wake Forest University. The technology could speed up the drug discovery process by as much as 10,000 times, according to company and university officials.

Nano firm teams with WFU to accelerate drug discovery

Winston-Salem, NC | Posted on August 10th, 2010

NanoMedica, Inc. has leased office space in the Piedmont Triad Research Park and signed a license option with Wake Forest for a technology called "Lab-on-Bead" that makes use of tiny beads to match drugs to disease markers.

The technology was developed by Jed Macosko, an associate professor of physics at Wake Forest who now also serves as NanoMedica's chief innovation officer. Co-inventor and fellow Wake Forest physics associate professor Martin Guthold is chief science officer; the company's chief technology officer is physics department Chairman Keith Bonin.

Macosko said that in the Lab-on-Bead process, nanoscopic plastic beads are studded with chemical "pins" that match up to a unique molecular "barcode" associated with a drug candidate.

The beads allow for rapid matching between the proteins specific to a particular disease and a drug showing characteristics that may act on that disease. The effect, Macosko said, is that the Lab-on-Bead process could screen 10,000 times more molecules in search of good drug candidates as current robotics-based methods.

"It does that by miniaturizing everything and putting essentially a whole laboratory onto a bead, instead of having to do each individual reaction in its own test tube," Macosko said.

A peer-reviewed paper on the technology will be published in the Journal of Molecular Recognition, and the Wake Forest inventors are working with NanoMedica CEO and founder Roger Cubicciotti to bring Lab-on-Bead to market. Cubicciotti founded NanoMedica in 2001 in New Jersey but has now relocated himself and the company to Winston-Salem.

The deal with Wake Forest gives NanoMedica one year to work with the technology to determine market feasibility before committing to a license. The company first began working with the university in 2003, Cubicciotti said.

The commercial vision for Lab-on-Bead is to "discover more with less," he said. The company initially would partner with companies that hold enormous libraries of potential drug candidates to offer molecules that other firms could then try to develop into drugs. Big pharma companies could also pay to apply the technology to their own molecular libraries to efficiently narrow down the list of those worth further development.

Starting small

NanoMedica is starting out as a small presence in Winston-Salem, with two technical employees so far besides its scientific principals. Cubicciotti said the company may have six employees by the first quarter of next year.

He moved his company because of its connection to Wake Forest but also because the state has done an excellent job supporting small companies like his that have the potential to grow, Cubicciotti said.

The N.C. Biotechnology Center, for example, provided $75,000 in funding for the research behind Lab-on-Bead.

"I've been extremely impressed by North Carolina's strategy in defining a unique signature at the crossroads of medicine and nanotechnology," he said. "It's impressive to see agencies focused not only on economic development, but also on attracting talent and fostering collaborations between companies and universities."

Cubicciotti singled out the Biotech Center's Center of Innovation for Nanobiotechnology for helping it navigate state resources and make introductions to other universities, including at N.C. A&T State University in Greensboro. The Center of Innovation for Nanobiotechnology, or Coin, was started as a joint project of N.C. A&T, UNC-Greensboro and Wake Forest to foster collaborations between industry and academics.

Brooks Adams, Coin's director, said his organization serves startups and companies like NanoMedica that are relocating to the area. He said he has invited Cubicciotti to join his board of directors.

"We're all about making resources in the state known to such people," Adams said. "There's no complete compendium available, so giving people a way to know about each other is a way to make things happen."

Adams said one of Coin's projects is to provide such a compendium online. A beta version of such a database is available now at the project's website, www.nc-coin.org.

NanoMedica Inc.
CEO: Roger Cubicciotti
Address: 101 N. Chestnut St.
Winston-Salem 27101
Phone: (336) 608-6010
Website: www.nanomedica.com

####

For more information, please click here

Contacts:
Bert Woodard
Next Level Communications (www.nextlevelcom.net)
For Piedmont Triad Partnership (www.piedmonttriadnc.com)
336-978-0021

Copyright © The Business Journal of the Greater Triad Area

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

Possible Futures

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Researchers create a first frequency comb of time-bin entangled qubits: Discovery is a significant step toward multi-channel quantum communication and higher capacity quantum computers April 28th, 2016

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Academic/Education

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

The Ottawa Hospital Research Institute uses the ZetaView from Particle Metrix to study membrane microparticles as potential biomarkers for underlying diseases April 12th, 2016

FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium April 5th, 2016

SUNY Poly, in Collaboration with the George Washington School of Medicine and Health Sciences and Stony Brook University, Demonstrates Pioneering Method to Visualize and Identify Engineered Nanoparticles in Tissue March 25th, 2016

Nanomedicine

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Announcements

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Nanobiotechnology

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic